Takashi Shimada
Förmögenhet: 181 487 $ per 2026-05-31
Förmögenhet: 181 487 $ per 2026-05-31
Takashi Shimada is currently Chairman at KMT Hepatech, Inc. since 2017, Chairman at PhoenixBio USA Corp.
since 2018, and President & Representative Director at PhoenixBio Co., Ltd. since 2018.
Formerly, Mr. Shimada was Director & Administration Manager at Institute of Immunology Co., Ltd.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
PHOENIXBIO CO., LTD. 1,68 % | 2025-09-30 | 68 300 ( 1,68 % ) | 181 487 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| PHOENIXBIO CO., LTD. | President | 2018-06-28 |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Ordförande | 2018-06-01 |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Ordförande | 2017-12-01 |
| Företag | Position | Slut |
|---|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Administrativ Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Commercial Services |
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Health Technology |
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
Välj din utgåva
All finansiell information anpassad till den nationella nivån